244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells

The epidermal growth factor receptor (EGFR) is known to play a critical role in non-small cell lung cancer(NSCLC). Several EGFR tyrosine kinase inhibitors(TKIs), such as gefitinib, have been used as effective clinical therapies for patients with NSCLC. Unfortunately, acquired resistance to gefitinib...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Zhang, Yi, Yao, Ke, Shi, Chengcheng, Jiang, Yanan, Liu, Kangdong, Zhao, Song, Chen, Hanyong, Reddy, Kanamata, Zhang, Chengjuan, Chang, Xiaoyu, Ryu, Joohyun, Bode, Ann M., Dong, Ziming, Dong, Zigang
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4792556/
https://ncbi.nlm.nih.gov/pubmed/26517520
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki